• LAST PRICE
    0.7960
  • TODAY'S CHANGE (%)
    Trending Down-0.0190 (-2.3313%)
  • Bid / Lots
    0.8300/ 2
  • Ask / Lots
    0.8350/ 3
  • Open / Previous Close
    0.8000 / 0.8150
  • Day Range
    Low 0.7960
    High 0.8201
  • 52 Week Range
    Low 0.6930
    High 4.5000
  • Volume
    46,099
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.815
TimeVolumeGENE
09:32 ET22000.8
09:56 ET76920.8
11:20 ET10000.8163
11:24 ET20000.813856
11:45 ET1000.82
12:16 ET7000.8201
12:48 ET18200.8201
01:10 ET1000.81
01:15 ET3000.81
01:35 ET3000.801
01:55 ET24050.81
02:04 ET16110.81
02:06 ET1000.8075
02:09 ET17000.8099
02:36 ET1000.807549
02:44 ET2590.81
02:47 ET1000.8051
02:49 ET10000.805
03:09 ET10000.8
03:18 ET23000.7971
03:20 ET5000.797
03:21 ET3000.796999
03:41 ET2090.796
03:54 ET57610.7963
03:56 ET1000.796
03:57 ET22000.796
03:59 ET35310.796
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGENE
Genetic Technologies Ltd
6.5M
-0.4x
---
United StatesSYRA
Syra Health Corp
4.2M
-0.7x
---
United StatesCMPD
CompuMed Inc
4.8M
-27.3x
---
United StatesMDCE
Medical Care Technologies Inc
4.3M
0.0x
---
United StatesMDRM
Modern Mobility Aids Inc
4.6M
-0.8x
---
United StatesALBT
Avalon Globocare Corp
3.3M
-0.1x
---
As of 2024-09-18

Company Information

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Contact Information

Headquarters
60-66 Hanover St, FitzroyMELBOURNE, VIC, Australia 3065
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Peter Rubinstein
Chief Executive Officer
Simon Morriss
Chief Financial Officer, Company Secretary
Mark Ziirsen
Chief Executive Officer - EasyDNA
Kevin Camilleri
Chief Scientific Officer
Richard Allman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.5M
Revenue (TTM)
$5.2M
Shares Outstanding
8.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.13
EPS
$-1.85
Book Value
$0.28
P/E Ratio
-0.4x
Price/Sales (TTM)
1.2
Price/Cash Flow (TTM)
---
Operating Margin
-157.67%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.